title: Premature ejaculation: current and future treatments.
abstract: Premature ejaculation (PE) is recognized to be the most common male sexual disorder. PE provides difficulties for professionals who treat this condition because there is neither a universally accepted definition nor a medication approved by the Food and Drug Administration (FDA). Despite these shortcomings, physicians continue to diagnose their patients with PE according to major guidelines and treat them with either behavioral therapies or off-label medications. This review focuses on current and emerging treatment options and medications for PE. Advantages and limitations of each treatment option are discussed in the light of current published peer-reviewed literature.
authors: Department of Urology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.
authors: Levent
authors: L
authors: Gurkan
authors: Matthew
authors: M
authors: Oommen
authors: Wayne J G
authors: WJ
authors: Hellstrom
mesh_terms: D000779:Anesthetics, Local; D001521:Behavior Therapy; D002997:Clomipramine / Q000627:therapeutic use; D004542:Ejaculation; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D011318:Prilocaine / Q000008:administration & dosage; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000523:psychology / Q000628:therapy*
chemical_list: D000779:Anesthetics, Local; D002997:Clomipramine; D008012:Lidocaine; D011318:Prilocaine; D017367:Selective Serotonin Reuptake Inhibitors